Evolocumab May Be Best Option for Statin Intolerance

ACC Conference Reporter

ACC.16 | CHICAGO — Among patients with very high LDL levels and confirmed muscle-related statin intolerance, evolocumab (Repatha) appears to achieve greater reductions in LDL cholesterol levels than ezetimibe (Zetia), the phase III GAUSS-3 trial showed. Read More >>>

Keywords: ACC Annual Scientific Session

< Back to Listings